The EU’s medicines regulator said on Tuesday it was “firmly convinced” the benefits of AstraZeneca’s vaccine outweigh potential risks, insisting there was no evidence linking it to blood clots after several nations suspended the shot over health fears.
“We are still firmly convinced that the benefits of the AstraZeneca vaccine in preventing Covid-19 with its associated risk of hospitalisation and death outweigh the risk of these side effects,” EMA chief Emer Cooke said Tuesday.
“At present there is no indication that vaccination has caused these conditions,” she added, echoing the WHO and drugmaker AstraZeneca itself.
Cooke noted however that the regulator was “looking at adverse events associated with all vaccines”.
Experts at both the World Health Organization and the European Medicines Agency held talks on the vaccine on Tuesday, with the European organisation expected to publish conclusions Thursday.
France and Italy welcomed the news from the EMA.
“Today’s preliminary statements from EMA are encouraging,” said a joint statement from French President Emmanuel Macron and Italian Prime Minister Mario Draghi.